Evidence map›Paper›PMID 41571985›Full record

ReviewNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2026

The spectrum of bipolar disorder in older adults.

Lisa T Eyler, Federica Klaus, Angelina Van Dyne, Hui Xin Ng, Annemiek Dols, Martha Sajatovic

Abstract readReview
PubMed Publisher
In one paragraph

Review in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Neuropsychiatric illness in the later years of life: summary and synthesis.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lisa T EylerDepartment of Psychiatry, University of California San Diego, La Jolla, CA, USA. lteyler@health.ucsd.edu.
Federica KlausDepartment of Psychiatry, University of California San Diego, La Jolla, CA, USA.
Angelina Van DyneSan Diego State University/University of California San Diego Joint Doctoral Program in Clinical Psychology, San Diego, CA, USA.
Hui Xin NgDepartment of Cognitive Science, University of California San Diego, La Jolla, CA, USA.
Annemiek DolsDepartment of Psychiatry, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht, The Netherlands.
Martha SajatovicCase Western Reserve University School of Medicine, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.

Funding

Otsuka America Pharmaceutical (Otsuka America Pharmaceutical, Inc.) N/ATeva Pharmaceutical Industries (Teva Pharmaceutical Industries Ltd.) N/A
6 · The paper itself

Abstract

The absolute number and relative proportion of individuals with older-age bipolar disorder (OABD) is expected to rise due to the global aging of the population, necessitating a greater understanding of the unique characteristics of OABD and the trajectory of aging with BD in order to improve the health span of people with BD. This review summarizes current knowledge on OABD, examining its clinical presentation, neurobiology, and treatment, as well as identifying key gaps and future directions for research. OABD is characterized by relatively greater cognitive impairment and somatic burden, despite potentially reduced mood symptom severity compared to younger-age bipolar disorder (YABD). This significantly impacts functional outcomes in older age, highlighting the need for age-adjusted clinical strategies. Individual differences in illness course, treatment history, and psychotic features influence the clinical presentation and prognosis in OABD. One powerful strategy to better understand OABD is to bring together existing data from across the globe through large-scale collaborations. In the realm of BD, this is exemplified by several ongoing efforts including the Global Aging and Geriatric Experiments in Bipolar Disorder (GAGE-BD) initiative and the Enhancing NeuroImaging Genetics through Meta-Analysis Bipolar Disorder (ENIGMA-BD) working group. Evidence on the trajectory of bipolar disorder (BD) across the lifespan is mixed, with some individuals showing accelerated cognitive and biological aging. Biomarker studies reveal overlaps between YABD and OABD, but also suggest age-specific alterations in inflammation and oxidative stress pathways. Lithium remains a first-line pharmacological treatment in OABD, with emerging evidence supporting other pharmacologic and behavioral interventions, although large-scale, age-specific trials remain limited. Neuromodulation treatment approaches appear promising but remain relatively unexplored in OABD. The review highlights current knowledge gaps, particularly the need for longitudinal research to identify early predictors of impairment, and to guide potential preventative strategies. This summary emphasizes the potential of global consortia and multi-center studies to deepen insights into BD aging trajectories with high generalizability. Ultimately, a lifespan approach that incorporates lived experience, early intervention, and global collaboration is essential to promoting health and well-being in individuals with OABD.

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.